Crunching the numbers for RAPP... Refresh in a moment for the full analysis.
Rapport Therapeutics, Inc. (RAPP)
Healthcare
mixed
$34.17
Updated: 2026-04-12
53
TradeApes Score
hold
Financial Strength
60
Healthy
Operating Trend
40
Weak
Valuation
50
Mixed
Capital Allocation
50
Mixed
Risk
80
Strong
Key Findings
+
Low leverage — net debt/EBITDA below 1×
−
Negative ROIC — business destroying value on invested capital
See the full analysis
Quarterly financials, DCF valuation model, Watchlist, and Stock Screener.
Create Free Account
Scores and valuations are model outputs, not investment advice. TradeApes does not provide financial, tax, or investment advice.